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Treatment of Mild Asthma With Inhaled Corticosteroids: 
Is Discontinuation of Therapy Possible?
Pierre M. van Grunsven, MD; Edward Dompeling, PhD, MD;
Constant P. van Schayck, PhD; Johan Molema, PhD, MD;
Hans Folgering, PhD, MD; Chris van Weel, PhD, MD
Background: This study investigated if  long-term therapy with inhaled corticosteroids could be 
discontinued in mild asthma when patients are in a clinically stable phase of the disease. Data 
were derived from a 2-year randomized, controlled, bronchodilator intervention study in family 
practice. Methods: The experimental (stop-steroid) group consisted of 19 asthmatic patients who 
had used inhaled corticosteroids daily during at least the year preceding this study and who 
stopped using these drugs because of participation in the bronchodilator intervention study. The 
control (no-steroid) group consisted of 70 patients with asthma who had not used corticosteroids 
in the year preceding the study. At the start of the study (8 weeks after stopping steroids), the two 
groups were completely comparable in all other relevant characteristics. During the 2-year study, 
patients were treated only with a bronchodilator (salbutamol or ipratropium bromide). Outcome 
measures were: exacerbations, symptoms, annual decline in forced expiratory volume in 1 second 
(FEVj), annual change in nonspecific bronchial responsiveness (PC2o-histamine), and the need 
fo r  additional corticosteroid therapy because o f  symptoms of increased airway obstruction. 
Results: In the stop-steroid group, 12 o f 19 patients (63%) dropped- out during the study period 
because o f a deterioration of their clinical condition and need for additional (inhaled) corticos­
teroid treatment. In the no-steroid group, only eight patients dropped out for this reason (11%). In 
the stop-steroid group, who did not use steroids for  at least 1 year, the annual FEV¡ decline was 
much larger than in the comparison subjects (165 40 ml/yr). Conclusions: Stopping mainte­
nance treatment with inhaled corticosteroids may not be advisable in all patients with mild asthma. 
Instead of stopping or interrupting treatment, family physicians are advised to determine the 
minimal effective daily dose o f  inhaled corticosteroids for  each individual patient that provides 
adequate control of the disease.
(Fam Med 1996;28:46-51.)
The current understanding that inflammation is a 
major pathophysiologic mechanism in asthma1 has 
resulted in a shift in treatment policy toward the early 
introduction of inhaled corticosteroids.2’3 In addition, 
some recent studies4'6 have suggested that inhaled cor­
ticosteroids can improve the long-term outcome of 
asthma. The tendency toward early use of inhaled ste­
roids is strengthened by the finding in two independent 
studies that continuous therapy with bronchodilators,
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the usual alternative to steroid treatment, may have 
adverse effects on the control of asthma7 and the pro­
gression of asthma.8 Since continuous therapy with 
bronchodilators may be detrimental, treatment with 
inhaled corticosteroids is probably the only currently 
available therapy that has been shown to improve the 
long-term course of asthma.
Since the majority of patients with asthma are 
treated in family practices,9,10 family physicians will 
be prescribing this therapy for a growing number of 
patients. An important question for family physi­
cians and patients is whether treatment with in­
haled corticosteroids can be interrupted or stopped 
when patients are in a stable phase of their dis­
ease. Since inhaled steroids do not have a direct
sym ptom -reliev ing  effect, patient compli­
ance with this medication is a major prob­
lem," and patients may even ask their fam- Figure 1
ily physician to stop maintenance treatment 
with inhaled steroids when their asthma is 
stable. Although inhaled steroids have rela­
tively mild side effects, oral candidiasis, hoarse­
ness, and irritation o f  the oropharynx may oc­
cur, and systemic effects may develop when 
doses of X00 ¡.ig or more are used.1-' All these 
aspects make the above question very relevant.
If corticosteroids ''cure” the underlying 
mechanisms o f  asthma and chronic bronchi­
tis to some extent, steroid treatment can prob­
ably be interrupted. If they only suppress in­
flammation temporarily, discontinuation of  
steroids might be difficult. »Some information 
is available about the effects o f  stopping treat­
ment with inhaled corticosteroids in patients 
referred for specialist treatment. In one study 
with moderate-to-severe asthmatic children, 
stopping inhaled steroids appeared to cause 
trouble.“ llaahtela et al showed that dis­
continuation o f  treatment with inhaled ste­
roids in mild asthma often was accompanied 
by exacerbation o f  the disease and may have
I *7
resulted in irreversible loss o f  lunu function.11
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A tola I of 5 24 patients were selected al live start o f  the 2 -year h touch oUilator trial; 3(H) 
patients did not participate in the study tor several reasons (see arrows). O f the 224 
patients who eventually took pan in the hronehodilator trial, only patients with asthma 
tn ^ i ]  were used in this study. No dropouts occurred in the K-week washout period. At 
the start of the study, the stop-steroid gtrnup had \ {) asthmatic patients. Due to dropout 
alter I and 2 years of study, only 10 and .S patients remained, respectively. The ihi- 
sieioid group had 70 asthmatic patients. After I and 2 years of study, only 62 and 54 
patients remained, respectively.
In another studv with mild asthmatic adults,
it was shown that improvements in asthma ! ' "m",vr
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n  »
could be maintained lor at least 3 months al ter ............ .... - ......- — ' —......... ....... . ............ ..................................
stopping steroid treatment.1' No studies have
been performed with patients from family practice deviations below their predicted value1" but more than
who had not been referred for specialist treatment. 50W o f  the p r e d ic te d  v a lu e )  and /or  b ron ch ia l
Since most o f  these patients probably have mild hyperresponsiveness to histamine (provocative con-
asihma, it seems relevant to investigate the possibili- centration o f  histamine that produces a 207c fall in 
ties ol stopping inhaled steroids in these patients. FEV, |PC.„I, and PO'^SK mg/ml). Exclusion criteria 
1’his study assessed the effects o f  stopping treat- were: dependency on oral corticosteroids, chronic
heart failure, m alignant disorders, or other life-ment with inhaled corticosteroids on long-term con­
trol and progression o f  asthma in a family practice. threatening diseases. Only patients with airway re- 
Data on Sl) patients with asthma from a previously activity due to asthma were included. The criteria for
published laruc intervention study were evaluated.*
M ethods
I 'a t i i ’tus
The stud\ population consisted of Ml) asthma pa­
tients who entered a 2-vear randomi/.ed, controlled
I *
study o f  hronehodilator therapy in family practice.*
Figure I shows the enrollment o f  the subjects, Pa­
tient selection and the inclusion and exclusion crite­
ria o f  the intervention study have been described in matie patients who had continuously used (inhaled) 
detail elsewhere.' Twenty nine family physicians were 
asked to select all their p a t ie n ts  aged 30 or older with 
symptoms o f  asthma or chronic bronchitis. Inclusion 
criteria included only patients with a mild-to-moder- 
ate airway obstruction (forced expiratory volume in 
I second'({TAM or FH W H V C  al least two standard
the diagnosis o f  asthma were based on the standards 
o f  the American Thoracic Society .17 Asthma was de­
fined as the combination of: 1 ) reversible obstruction 
(FHVt increased by more than I.V/r o f  the baseline 
value 60 minutes alter the administration o f  SO j.tg 
ipratropium bromide and 4 0 0  |.tg sulbutamol ), 2) bron­
chial hyperresponsiveness to histamine (PC,.,,<8 mg/  
ml), 3) dyspnea, and 4 )  allergy and/or wheezing.
The expérimental (stop-steroid) group had 19 asth-
eortieosteroids daily during al least 1 year preceding  
the study and stopped because o f  participation in the 
hronehodilator intervention study. 'Fhe.se patients had 
been given permission by their physician to stop cor­
ticosteroids, and they entered an S-week washout  
period before the start o f  the hronehodilator study.
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during which inhaled corticosteroid treatment (and 
other pulmonary medication) was stopped. During this 
period, only as-needed inhaled salbutamol or ipratro­
pium bromide were prescribed. No patients had an 
exacerbation during this washout period and were 
therefore not excluded from the study.
The control (no-steroid) group consisted of the re­
maining 70 asthmatic patients who had not used in­
haled corticosteroids in the year preceding the study. 
The clinical characteristics of the stop-steroid and no­
steroid groups are shown in Table 1. At the start of the 
study, the two groups had no significant differences.
The study was approved by the Medical Ethics 
Committee of the University of Nijmegen. All pa­
tients gave informed consent.
Outcome Measures
The stop-steroid and no-steroid groups were followed 
for 2 years while receiving standard bronchodilator treat­
ment. The main outcome measure during this period 
was the annual decline, if any, in FEV,. On the basis 
of earlier research,6’8 it was determined that the mini­
mum detectable difference in FEVi decline was 120 
ml/yr, with an individual standard deviation of the
FEVj decline of 100 ml. With an alpha of ,05 and a
power of .8, the number of patients who could be evalu­
ated had to be at least 10 in each study group.
Secondary outcome measures during this period were 
the number of exacerbations, severity of symptoms, and 
annual change in nonspecific bronchial responsiveness 
(PC2o-histamine). An important outcome measurement 
and endpoint in this study was the need for corticoster­
oid therapy due to too severe or too many exacerba­
tions. The category “too severe exacerbations” was de­
fined as exacerbations not sufficiently treated by a 10- 
day course of oral prednisone, adding broad spectrum 
antibiotics if necessary. The category “too many exac­
erbations” was more than two exacerbations annually.
Measurements
Respiratory Symptoms. The severity of respiratory 
symptoms (cough, phlegm, dyspnea) was assessed 
weekly by each subject on a scale of 0-4 and recorded 
in a diary. A score of “4” indicated worst symptoms 
and “0” indicated no symptoms. The total score was 
computed by adding the cough, phlegm, and dyspnea 
scores (maximum 4 points each) to yield a total score. 
The highest (most symptomatic) possible score was 12.
Exacerbations. Exacerbations were defined accord­
ing to Fletcher et al,18 with the modifications of Boman 
et al19 as the occurrence of mucopurulent sputum, 
cough, and at least one of the following symptoms: 
general malaise, symptoms of common cold, fever, 
dyspnea, increased sputum production, increased spu­
tum thickness, foul-tasting sputum, or increased diffi- 
culty of expectoration. In case of an exacerbation,
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Table 1
Patient Characteristics*
Experimental Control 
Variable "Stop-steroid" Group “No-steroid” Group
Number 19 70
Age, years 56(12) 51(12)
Gender, male/female 6/13 35/35
Symptom score 4.6 (1.5) 4.9 (1.7)
# of packs/year of smoking 12(10) 12(16)
Smokers, yes/no/no data 2/8/9 27/38/5
Allergy,** yes/no/no data 5/6/8 24/40/5
FEV, % predicted 71 (19) 72 (20)
FEVj/IVC, % 62(15) 61(11)
Reversibility FEVj, % predicted 17 (10) 14 (11)
PC^Q-histamine, mg/ml .6 1.3
* Characteristics are of the 19 patients of the stop-steroid group 
(continuous use of inhaled corticosteroids during the year preceding the 
study) and the 70 patients of the no-steroid group (no use of corticosteroids 
during the pre-study period). Standard deviations or ranges are in 
parentheses. Differences in dichotomic variables were statistically 
compared using the chi-square test and were compared in normally 
distributed variables using the unpaired Student’s t test. No statistically 
significant differences were present.
** Allergy was defined as at least one positive test out of seven RAST 
(Radio Allergo Sorbent Tests).
FEVj—Forced expiratory volume in 1 second as a percentage of the 
predicted value
ÏVC—Inspiratory vital capacity
PC2o-histamine—Provocative concentration of histamine (the dose of 
histamine producing a 20% fal 1 in FEV j). Geometric mean PC2q is given.
a 10-day tapering-down course of oral prednisone was 
given. (25,25,20,20,15,15,10,10,5, 5 mg).
FEVi, PC2o Histamine and Reversibility of Airway 
Obstruction. No bronchodilating medication was 
taken for at least 8 hours before the assessments of 
airway obstruction. Measurements of FEV 1 were per­
formed with the Microspiro HI-298 spirometer® 
(Chest Corporation, Japan) by two qualified labora­
tory technicians.20 Patients had to perform three sat­
isfactory forced vital capacity (FVC) maneuvers on 
all occasions. Data were taken from the curve with 
the highest sum of FVC and FEV|. The bronchial re­
sponsiveness to histamine was measured using the 
method described by Cockcroft et al21 and expressed 
as the PC20-histamine value. After the FEV! had re­
turned to baseline value, the increase in FEV, 60 min­
utes after the inhalation of both 400 jo.g salbutamol 
and 80 |ig ipratropium bromide was assessed.
Smoking Behavior. The number of cigarettes smoked 
per day was recorded by the patients in a weekly re­
port. The smoking history was retrospectively as­
sessed and quantified in pack years.
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Effects oi' Stopping Treatment With Corticosteroids
* *
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The scores o f  cough, phlegm, and 
dyspnea were combined in the total 
sym ptom  score. The annual FEVi de­
cline w as determined by linear regres­
sion o f  FEVi over the course o f  time 
(m axim um  o f  seven measurements). 
PC.i, values were -log transformed prior 
to analysis. The annual changes o f  PC\0 
were estimated by linear regression of  
’log PC:,i in the course o f  time (maxi­
mum o f  five measurements).
The influence o f  stopping treatment 
with inhaled corticosteroids on the 
o u tco m e  variables was assessed  by 
m u l t i p l e  a n a l y s i s  o f  v a r ia n c e  
(M A N O V A ) ,  adjusting for age. gen ­
tler, height, smoking, pack years, al- 
leruv ,  i n i t i a l  P C \ ,  and F EV, ,
•k r *  » ' '  1
reversibility o f  obstruction, and bron- 
ehodilator treatment during the study.” 
The relation between clinical charac­
teristics and the annual FEVi decline  
after stopping treatment with steroids 
in the stop-steroid group was also in­
vest igated  by means o f  M ANO VA.  
The effects o f  slopping steroids on de­
cline in lung function and change in 
bronchial hyperresponsiveness, exac­
erbations, and symptoms were only in­
vestigated in subjects who could slop  
using steroids for at least I year (ex ­
planatory analysis ,  no intcntion-to-  
treat analysis).
Table shows the ellect ol stoppim* tieatment with eoiiicosteiuids on symptoms, exacerbations, 
the annual decline m H*Yt ttorced expiratory volume in I second!, and l‘t \ (l (provocative 
concentration ot histamme ponlucm^ a ’US lall in H\V,) in patients with mild asthma who 
could stop usmji cotticosteiouls at least during I year. Standard errors til the mean are in 
parentheses. Ihtteiences weie tested by means oi the unpaired Student’s / test.
Treatment During 2-year Follow-up
Results
In the stop-steroid group, 12 o f  the 
l ‘J patients (ft.V/i) dropped out during 
(he 2-year study period because o f  a 
deterioration o f  their clinical condition 
and need for additional (inhaled) cor­
ticosteroid treatment, vs only eight o f  
the 70 patients ( 117c) in the no-steroid 
group (chi-square=20.1 . / ’<.()()() I ). O f  
the 12 dropouts from the stop-steroid 
group, eight needed additional corti­
costeroids during the first (i months o f  the bronehodi-
« '/ft «Mei'j* .» . r /v • w« t  m «tv» i f * w
All patients received bronchodilator therapy alone later trial (Table 2).
during the 2-year study period, either continuously When the patients who could continue broncho-
(salbutamol 400 |.tg or ipratropium bromide 40  |ig, dilator therapy without inhaled steroids during at least
four times daily) or on demand (only dry powder cap­
sules o f  salbutamol 400  |.ig or ipratropium 40 [ig dur­
ing complaints or exacerbations).* No inhaled steroids
I year were analyzed, the fo llowing data were found 
(Table 3). The annual FliV. decline was lanzer in the 
stop-steroid group (165 ml/yr) than in the no-steroid
or eroinoglycate were permitted. Patients using salbuta- group (40 ml/yr) (Z ^ .022).  N o  dilferenees between 
mo! during the first year crossed over to ipratropium groups were found with respect to symptoms, exacer- 
hronude during the second year and vice versa.* hâtions, and the annual change in PC*».
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No feature could predict the effect of stopping in­
haled corticosteroids at the start of the study. Allergy, 
initial FEV x and PC20, reversibility of obstruction, and 
smoking behavior before and during the study were 
all unrelated to the difference in annual decline in 
FEV] in the stop-steroid and no-steroid groups.
Discussion
Long-term treatment of asthma with inhaled corti­
costeroids is becoming increasingly important for 
family physicians. Two recent guidelines about the 
therapeutic management of asthma advocated the 
early introduction of inhaled corticosteroids in patients 
with asthma.2*3 Since most patients with asthma are 
treated in primary care practices,9-10 and indications 
for the use of inhaled corticosteroids are increasing, 
family physicians will have to prescribe this kind of 
therapy for a growing number of patients. For family 
physicians, an important therapeutic question about 
treatment with inhaled corticosteroids is whether 
maintenance therapy with these drugs can be discon­
tinued when adequate control of the disease has been 
achieved. This question has not yet been addressed 
in a long-term follow-up study in patients selected 
from family practice. Therefore, it seemed appropri­
ate to study the ability to stop steroid therapy under 
close observation, as we did in this study.
This study shows that it is difficult to stop treat­
ment with inhaled corticosteroids in patients with mild 
asthma. Of the 19 patients in whom steroids were 
stopped, 12 (63%) needed additional inhaled corti­
costeroids during the 2-year study period, mostly 
during the first 6 months after stopping. This percent­
age was much higher than in the group of subjects 
not using steroids regularly (11 %). In the patients who 
stopped steroids and were able to continue treatment 
with bronchodilators alone (without inhaled steroids) 
for at least 1 year, the annual decline in ventilatory 
function was much higher than in the no-steroid group. 
However, no increased deterioration in bronchial 
hyperresponsiveness was found in the patients stop­
ping inhaled corticosteroids. Perhaps the PC20 had 
already declined during the washout period just be­
fore the start of the study.23,24
The high percentage of patients who needed addi­
tional corticosteroid therapy and the large decline of 
FEV i in the patients stopping treatment with steroids 
suggests that inhaled steroids do not cure but only 
suppress underlying disease processes. It even sug­
gests the existence of a “rebound” increase in airway 
inflammation and a consequent excessive increase in 
airway obstruction after the withdrawal of steroids. 
Short-term studies in asthma demonstrated a decline 
in FEVi and an increase in nonspecific bronchial 
responsiveness after withdrawal or dose reduction15 
of inhaled steroids.23-25 One long-term study in pa­
tients with asthma referred to specialist treatment also
showed a decline in FEV| level after stopping inhaled 
steroids.14 After stopping treatment with oral steroids 
or replacement by inhaled corticosteroids, fatal asthma26 
and severe asthma relapse27 may occur as late as 4—8 
months after discontinuation. Fortunately, none of the 
stop-steroid group in our study had fatal or near-fatal 
asthma after cessation of steroids. The syndrome of 
pseudorheumatism (myalgia, arthralgia, joint swell­
ing, etc) in some asthmatic patients stopping treatment 
with oral steroids28 might also suggest a rebound in­
crease in systemic and local inflammatory processes.
In origin, this study had another research question, 
and the information presented in this report represents 
a reanalysis of study data. A disadvantage of such a 
reanalysis is that the study protocol was not specifi­
cally designed for the purpose for which we used it. 
Therefore, the research reported here can only serve 
as an observational study. As a consequence, the study 
(stop-steroid) and comparison (no-steroid) groups do 
not really have a true experimental-control relation­
ship. Measuring dropouts as an outcome might have 
interfered with the main outcome measures of the 
study (FEVj decline, PC20 decline, etc), since the study 
was unblinded and not randomized. Patients in the 
stop-steroid group had already taken an inhaled ste­
roid for at least 1 year and could easily drop out dur­
ing the study on the basis of this pre-study medica­
tion experience. However, despite the many dropouts 
from the experimental (stop-steroid) group, we were 
still able to show a significantly faster decline of FEV! 
in this group than in the no-steroid group (165 vs 40 
ml/yr). A better design to answer this paper’s ques­
tion would have been a randomized, controlled, 
double-blind study in which one group of patients 
would continue and another group would discontinue 
the medication. Before firm conclusions can be drawn 
about the possibility of stopping inhaled steroids, such 
a study is absolutely necessary.
In spite of this limitation, we believe this study 
suggests that physicians should be careful in their deci­
sion when to stop inhaled steroids in patients with 
asthma. For this study, we selected only those patients 
who had mild degrees of airway obstruction (FEV i was 
75% of the predicted value), mild symptoms, and who, 
in the opinion of the responsible family physician, 
could potentially stop the use of inhaled corticoster­
oid therapy. No measured differences were detected 
in characteristics at the start of the study between the 
patients who had used inhaled corticosteroids and 
those who had not, 8 weeks after stopping the steroid 
treatment. During this 8-week washout period, we ob­
served whether the symptoms were well controlled 
by bronchodilators alone and if no exacerbations or 
signs of increasing airway obstruction developed. If 
patients had not responded well to this bronchodilating 
therapy alone, they would have been excluded from the 
study. However, this did not occur.
V*,/i  « <¿*1 J ,  I Y l / „  I
As mentioned earlier, at the start o f  the study the 
stop-steroid and no-steroid groups were identical for 
all relevant characteristics. As a consequence, their 
needs for steroid therapy should also be identical. 
Therefore, the use o f  steroids seems to pose a risk in 
patients in that future discontinuation o f  the drug is 
associated with a deterioration in lung function. The 
majority of the stop-steroid group had been referred 
to the lung specialist before the start of the use o f  
steroids. Therefore, we could overtake the mean ini­
tial FBV| of this group o f  patients. The mean FEV, 
percentage predicted was 71 %, the same level as at 
the start of this study. However, the reason for refer­
ral in the stop-steroid group could have been an un­
stable (steroid-dependent) asthma. Theoretically, it is 
possible that the deterioration in lung function o f  the 
stop-steroid group was caused by this fact. In that case, 
an 8-week washout period would not have been long 
enough to eliminate the protective effect o f  steroids 
on the airways. Nonetheless, this study's data suggest 
that if a physician is considering stopping inhaled 
steroid therapy in a patient with apparently mild 
(stable) asthma, the patient must be monitored close­
ly for at least 6 months after slopping.
Conclusions
»Stopping maintenance treatment with inhaled cor­
ticosteroids in patients with mild asthma might be 
troublesome. In this observational study, about 60% 
o f  the patients needed additional inhaled corticoster­
oids after discontinuation o f  the drug, most o f  them 
during the first 6 months after stopping. In the pa­
tients who could continue without corticosteroids for 
al least 1 year, the annual decline in ventilatory func­
tion was much larger than in the comparison group. 
Instead of stopping inhaled steroids, family physi­
cians are advised to determine the minimal effective  
daily dose o f  inhaled corticosteroids that provides ad­
equate control o f  the disease in individual patients.
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